Attached files

file filename
S-1 - REGISTRATION STATEMENT - Virpax Pharmaceuticals, Inc.ea127899-s1_virpaxpharma.htm
EX-23.1 - CONSENT OF EISNERAMPER LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR TH - Virpax Pharmaceuticals, Inc.ea127899ex23-1_virpaxpharma.htm
EX-10.29 - INDEPENDENT CONTRACTOR AGREEMENT, DATED MAY 1, 2020, BETWEEN VIRPAX PHARMACEUTIC - Virpax Pharmaceuticals, Inc.ea127899ex10-29_virpaxpharma.htm
EX-10.28 - COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT, DATED AUGUST 25, 2020, BETWEEN T - Virpax Pharmaceuticals, Inc.ea127899ex10-28_virpaxpharma.htm
EX-10.27 - PAYCHECK PROTECTION PROGRAM TERM NOTE, DATED MAY 4, 2020, BETWEEN VIRPAX PHARMAC - Virpax Pharmaceuticals, Inc.ea127899ex10-27_virpaxpharma.htm
EX-10.26 - SECOND AMENDMENT TO THE SERVICES CONVERTIBLE PROMISSORY NOTE, DATED AS OF SEPTEM - Virpax Pharmaceuticals, Inc.ea127899ex10-26_virpaxpharma.htm
EX-10.25 - FIRST AMENDMENT TO THE SERVICES CONVERTIBLE PROMISSORY NOTE, DATED MARCH 25, 202 - Virpax Pharmaceuticals, Inc.ea127899ex10-25_virpaxpharma.htm
EX-10.24 - SERVICE PROVIDER CONVERTIBLE NOTE PURCHASE AGREEMENT, DATED AUGUST 29, 2019, BET - Virpax Pharmaceuticals, Inc.ea127899ex10-24_virpaxpharma.htm
EX-10.23 - AMENDMENT NO. 1 TO THE PROMISSORY NOTE DATED JANUARY 15, 2019, DATED APRIL 6, 20 - Virpax Pharmaceuticals, Inc.ea127899ex10-23_virpaxpharma.htm
EX-10.22 - PROMISSORY NOTE, DATED JANUARY 15, 2019, BETWEEN ANTHONY MACK AND VIRPAX PHARMAC - Virpax Pharmaceuticals, Inc.ea127899ex10-22_virpaxpharma.htm
EX-10.20 - PROMISSORY NOTE, DATED OCTOBER 1, 2018, BETWEEN ANTHONY MACK AND VIRPAX PHARMACE - Virpax Pharmaceuticals, Inc.ea127899ex10-20_virpaxpharma.htm
EX-10.6 - CONSULTING AGREEMENT BY AND BETWEEN VIRPAX PHARMACEUTICALS, INC. AND GERALD BRUC - Virpax Pharmaceuticals, Inc.ea127899ex10-6_virpaxpharma.htm
EX-10.5 - EMPLOYMENT AGREEMENT BY AND BETWEEN VIRPAX PHARMACEUTICALS, INC. AND ANTHONY MAC - Virpax Pharmaceuticals, Inc.ea127899ex10-5_virpaxpharma.htm
EX-10.4 - FORM OF INCENTIVE STOCK OPTION AWARD UNDER 2017 EQUITY INCENTIVE PLAN. - Virpax Pharmaceuticals, Inc.ea127899ex10-4_virpaxpharma.htm
EX-10.3 - FORM OF NONQUALIFIED STOCK OPTION AWARD UNDER 2017 EQUITY INCENTIVE PLAN. - Virpax Pharmaceuticals, Inc.ea127899ex10-3_virpaxpharma.htm
EX-10.2 - VIRPAX PHARMACEUTICALS, INC. 2017 EQUITY INCENTIVE PLAN. - Virpax Pharmaceuticals, Inc.ea127899ex10-2_virpaxpharma.htm
EX-4.3 - FORM OF CONSULTANT WARRANT - Virpax Pharmaceuticals, Inc.ea127899ex4-3_virpaxpharma.htm
EX-4.1 - SPECIMEN CERTIFICATE REPRESENTING SHARES OF COMMON STOCK OF VIRPAX PHARMACEUTICA - Virpax Pharmaceuticals, Inc.ea127899ex4-1_virpaxpharma.htm
EX-3.3 - BYLAWS OF VIRPAX PHARMACEUTICALS, INC., AS CURRENTLY IN EFFECT. - Virpax Pharmaceuticals, Inc.ea127899ex3-3_virpaxpharma.htm
EX-3.1 - CERTIFICATE OF INCORPORATION OF VIRPAX PHARMACEUTICALS, INC., AS CURRENTLY IN EF - Virpax Pharmaceuticals, Inc.ea127899ex3-1_virpaxpharma.htm

Exhibit 10.21

 

FIRST AMENDMENT TO THE PROMISSORY NOTE BETWEEN VIRPAX PHARMACEUTICALS, INC. AND ANTHONY P. MACK

 

This First Amendment to the Promissory Note dated October 1, 2018, this (“Amendment”) is entered into on April 6, 2020 (the “Effective Date”) between Virpax Pharmaceuticals, Inc., (“Virpax”) and Anthony P. Mack (“AM”). Virpax and AM may be collectively referred to herein as the “Parties.”

 

W I T N E S S E T H:

 

WHEREAS, the Parties entered into that certain Promissory Note dated October 1, 2018 (the “Note”) which described the terms under which AM would loan certain amounts to Virpax the terms under which Virpax would repay such amounts; and

 

WHEREAS, the Parties desire to amend the Note in order to extend the Maturity Date of the payment of the principal and provide for the payment of all interest accrued up to October 1, 2020.

 

NOW THEREFORE, the Parties in consideration of the mutual covenants and agreements hereinafter set forth agree as follows:

 

1. The Note is hereby amended as follows:

 

1.Amend Article 1 to extend the Maturity Date of the payment of the principal to October 1, 2020

 

2.Amend Article 2 to provide for the payment of all interest accrued up to October 1, 2020.

 

Except as amended hereby, all of the terms and conditions of the Note are hereby ratified and confirmed and shall remain in full force and effect.

 

IN WITNESS WHEREOF, the Parties have caused this Amendment to be executed by their duly authorized representatives as of the Effective Date.

 

By: /s/ Jeffrey Gudin  
Name: Jeffrey Gudin, EVP, Chief medical officer  

 

By the Holder: /s/ Anthony P. Mack  
Name: Anthony P. Mack, Chairman & CEO